Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective-Reference-Cited by-同舟云学术

Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective

Published:2019-12 Issue: Volume:83 Page:107154
ISSN:1476-9271
Container-title:Computational Biology and Chemistry
language:en
Short-container-title:Computational Biology and Chemistry

Author:

Boonma Thitiya,Nutho Bodee,Rungrotmongkol Thanyada,Nunthaboot Nadtanet

Funder

Asia Research Center

Chulalongkorn University and the Center of Excellence for Innovation in Chemistry

Ministry of Higher Education, Science

Research and Innovation

science, Mahasarakham University

National Science and Technology Development Agency

Publisher

Elsevier BV

Subject

Computational Mathematics,Organic Chemistry,Biochemistry,Structural Biology

Reference51 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Blach;Lancet Gastroenterol. Hepatol.,2017

2. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection;Mensa;Future Microbiol.,2019

3. Quinoxaline-based linear HCV NS3/4A protease inhibitors exhibit potent activity against drug resistant variants;Rusere;ACS Med. Chem. Lett.,2018

4. Hepatitis C virus resistance to protease inhibitors;Halfon;J. Hepatol.,2011

5. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review;Wu;World J. Gastroenterol.,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral proteases as therapeutic targets;Molecular Aspects of Medicine;2022-12

2. Titania Nanosheet Generates Peroxynitrite-Dependent S-Nitrosylation and Enhances p53 Function in Lung Cancer Cells;Pharmaceutics;2021-08-10

3. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors;VirusDisease;2021-04-29

4. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study;Journal of Biomolecular Structure and Dynamics;2021-01-11